Genomtec (GMT) Q3 2025 earnings summary

Executive summary

• Focus on R&D in molecular diagnostics, with Genomtec ID and OncoSNAAT as flagship projects.

• No significant revenue from product sales; income mainly from grants and one-off orders.

• Strategic goal is commercialization via partnerships, licensing, or technology sale.

• Company listed on Warsaw Stock Exchange since February 2023.

Financial highlights

• Revenue from sales for 9M 2025: PLN 15,000 vs. PLN 1,000 year-over-year.

• Net loss for 9M 2025: PLN -9,127,000 vs. PLN -9,326,000 year-over-year.

• R&D expenses increased to PLN 5,734,000 from PLN 1,912,000 year-over-year.

• Cash and equivalents at 30.09.2025: PLN 7,402,000.

• Equity at 30.09.2025: PLN 10,348,000.

Outlook and guidance

• No financial forecasts published.

• Commercialization of Genomtec ID and OncoSNAAT expected in coming years, pending successful partnerships.

• Future results depend on securing further grants, investor funding, and successful product launches.